Patents by Inventor Kenneth Allen Savin

Kenneth Allen Savin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Thiazolopyridinone derivates as MCH receptor antagonists
    Patent number: 7902356
    Abstract: The present invention relates to a melanin concentrating hormone antagonist compound of formula (I); wherein w, R1, q, p, R2, t, Ar1, L1, R3 and R4 are as defined, or a pharmaceutically acceptable salt, solvate, or enantiomer thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.
    Type: Grant
    Filed: December 16, 2005
    Date of Patent: March 8, 2011
    Assignee: Eli Lilly and Company
    Inventors: Albert Kudzovi Amegadzie, James Peter Beck, Kevin Matthew Gardinier, Erik James Hembre, James Craig Ruble, Kenneth Allen Savin, Brian David Wakefield
  • MCH receptor antagonists
    Patent number: 7838543
    Abstract: The present invention relates to a melanin concentrating hormone antagonist compound of formula (I); wherein Ar1, L1, R1, q, X, R2, R3, R4, and R5 are as defined, or a pharmaceutically acceptable salt, solvate, or enantiomer thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.
    Type: Grant
    Filed: December 16, 2005
    Date of Patent: November 23, 2010
    Assignee: Eli Lilly and Company
    Inventors: James Peter Beck, Brian David Wakefield, Frederic Laurent Cordier, Esteban Dominguez-Manzanares, Kevin Matthew Gardinier, Peter Michael Greenen, Kenneth Allen Savin
  • NOVEL MCH RECEPTOR ANTAGONISTS
    Publication number: 20090170913
    Abstract: The present invention relates to a melanin concentrating hormone antagonist compound of formula (I); wherein Ar1, L1, R1, q, X, R2, R3, R4, and R5 are as defined, or a pharmaceutically acceptable salt, solvate, or enantiomer thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.
    Type: Application
    Filed: December 16, 2005
    Publication date: July 2, 2009
    Inventors: James Peter Beck, Brian David Wakefield, Frederic Laurent Cordier, Esteban Dominguez-Manzanares, Kevin Matthew Gardinier, Peter Michael Greenen, Kenneth Allen Savin
  • Triazole derivatives as tachykinin receptor antagonists
    Patent number: 7320994
    Abstract: This application relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and its use as an inhibitor of the NK-1 subtype of tachykinin receptors, as well as a process for its preparation and intermediates therefor.
    Type: Grant
    Filed: April 22, 2003
    Date of Patent: January 22, 2008
    Assignee: Eli Lilly and Company
    Inventors: Albert Kudzovi Amegadzie, Kevin Matthew Gardinier, Erik James Hembre, Jian Eric Hong, Louis Nickolaus Jungheim, Brian Stephen Muehl, David Michael Remick, Michael Alan Robertson, Kenneth Allen Savin
  • Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
    Patent number: 7229987
    Abstract: The present invention relates to a melanin concentrating hormone antagonist compound of formula I: (I); or a pharmaceutically acceptable salt, solvate, enantiomer or prodrug thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.
    Type: Grant
    Filed: May 6, 2003
    Date of Patent: June 12, 2007
    Assignee: Eli Lilly and Company
    Inventors: Jochen Ammenn, James Ronald Gillig, Lawrence Joseph Heinz, Philip Arthur Hipskind, Michael Dean Kinnick, Yen-Shi Lai, John Michael Morin, Jr., James Arthur Nixon, Carsten Ott, Kenneth Allen Savin, Theo Schotten, Lawrence John Slieker, Nancy June Snyder, Michael Alan Robertson
  • Tachykinin receptor antagonists
    Patent number: 7179804
    Abstract: The present invention relates to selective NK-1 receptor antagonists of Formula (I); or a pharmaceutically acceptable salt thereof, for the treatment of disorders associated with an excess of tachykinins
    Type: Grant
    Filed: April 22, 2003
    Date of Patent: February 20, 2007
    Assignee: Eli Lilly and Company
    Inventors: Albert Kudzovi Amegadzie, Kevin Matthew Gardinier, Erik James Hembre, Jian Eric Hong, Louis Nickolaus Jungheim, Michael Alan Robertson, Kenneth Allen Savin